They said it at DeviceTalks Boston 2023

M&A AND FUNDING AT DEVICETALKS BOSTON

MedTech Innovator CEO Paul Grand discussed the challenges of raising capital for small companies, “When you’re at a small company, you’re always thinking about your next round of capital. What milestones do you need to achieve to unlock the next round of investors? You always want someone who has a plan.”

Referencing raising capital in the current economic climate, Grand said, “We’re not recession-proof, but we’re resilient. The money is out there. Funds that are only for medtech are looking for great investments.”

“Medical device IPOs and SPACs are extremely tough right now,” Greenberg Traurig patent attorney David Dykeman said. Dykeman predicts that “M&A is going to be the exit pathway for 2023.”

Boston Scientific Chair and CEO Mike Mahoney laid out his strategy for continued growth at his company: “We will focus on R&D, M&A and venture bets.” (Read more from Mahoney’s keynote here.)

Becton Dickinson President, CEO and Chair Tom Polen thinks the shift toward more biologics would create more opportunities for BD. His company continues to look for acquisitions in “very specific areas” that complement what it is doing.

Next >>